当前位置: X-MOL 学术Immunol. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Long-term omalizumab efficacy in allergic rhinitis.
Immunology Letters ( IF 4.4 ) Pub Date : 2020-08-13 , DOI: 10.1016/j.imlet.2020.08.002
Carlo Cavaliere 1 , Elona Begvarfaj 2 , Cristoforo Incorvaia 3 , Bruno Sposato 4 , Marco Brunori 5 , Andrea Ciofalo 6 , Antonio Greco 6 , Marco de Vincentiis 1 , Simonetta Masieri 6
Affiliation  

Background

Omalizumab therapy was found to be safe and effective as an add-on therapy for patients with poorly controlled severe asthma. Although several studies over the last decade have demonstrated its efficacy in other Immunoglobulin E related diseases, its use in such conditions is off-label.

Objective

This study aimed to assess the effectiveness of long-term therapy with Omalizumab in patients with persistent severe allergic rhinitis and inadequately controlled severe asthma.

Methods

Patients with poorly controlled severe asthma and persistent allergic rhinitis were enrolled and treated with Omalizumab for 36 months with every four-week subcutaneous administration. The efficacy assessment included the severity of AR symptoms every six months using Visual Analogue Scale, Asthma Control Test, nasal endoscopy, spirometry, and biomarkers (blood eosinophils and neutrophils, fractional exhaled nitric oxide, total IgE).

Results

Eleven patients aged between 26 and 70 years were enrolled, and 10 completed the study. A significant improvement of allergic rhinitis symptoms, Asthma Control Test, and lung function was observed. There was also a reduction in the status of the biomarkers at the end of the study.

Conclusion

Long-term therapy with Omalizumab was effective and safe in treating severe persistent allergic rhinitis and concomitant asthma.



中文翻译:

长期奥马珠单抗治疗过敏性鼻炎的疗效。

背景

发现奥马珠单抗疗法作为控制不佳的重度哮喘患者的附加疗法是安全有效的。尽管过去十年的几项研究证明了其在其他免疫球蛋白 E 相关疾病中的疗效,但其在此类情况下的使用是超说明书的。

客观的

本研究旨在评估长期使用奥马珠单抗治疗患有持续性重度过敏性鼻炎和控制不佳的重度哮喘患者的有效性。

方法

患有控制不佳的重度哮喘和持续性过敏性鼻炎的患者被纳入并使用奥马珠单抗治疗 36 个月,每 4 周皮下给药一次。疗效评估包括每六个月使用视觉模拟量表、哮喘控制测试、鼻内窥镜检查、肺活量测定和生物标志物(血液嗜酸性粒细胞和中性粒细胞、呼出的一氧化氮分数、总 IgE)评估 AR 症状的严重程度。

结果

招募了 11 名年龄在 26 至 70 岁之间的患者,其中 10 名完成了研究。观察到过敏性鼻炎症状、哮喘控制测试和肺功能的显着改善。在研究结束时,生物标志物的状态也有所下降。

结论

长期使用奥马珠单抗治疗严重的持续性过敏性鼻炎和伴随的哮喘是有效且安全的。

更新日期:2020-09-09
down
wechat
bug